Trial Profile
Does caffeine reduce rosuvastatin-induced protection against ischemia-reperfusion injury?
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary) ; Caffeine
- Indications Hyperlipidaemia
- Focus Pharmacodynamics
- 19 Aug 2009 Status changed from recruiting to completed.
- 01 Jun 2009 Results published in Arteriosclerosis Thrombosis and Vascular Biology.
- 09 Oct 2007 Status change from initiated to recruiting